Research programme: axon regeneration therapies - Alseres Pharmaceuticals
Alternative Names: ALSE-100; CBP-15 calcium-binding protein; MDP14; OCM protein; OncomodulinLatest Information Update: 19 Jan 2011
At a glance
- Originator Childrens Hospital Boston
- Developer Alseres Pharmaceuticals
- Class Calcium binding proteins
- Mechanism of Action Neuron stimulants; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Suspended Brain injuries; Cardiomyopathies; Eye disorders; Spinal cord injuries
Most Recent Events
- 19 Nov 2008 Pharmacodynamics data from a preclinical trial in Eye disorders presented at the the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
- 26 May 2008 The Regenerative Therapeutics programme is available for licensing (http://www.alseres.com)
- 08 Jun 2007 Boston Life Sciences is now called Alseres Pharmaceuticals